These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 34378540)
21. 6-Amino-2,4,5-trimethylpyridin-3-ol and 2-amino-4,6-dimethylpyrimidin-5-ol derivatives as selective fibroblast growth factor receptor 4 inhibitors: design, synthesis, molecular docking, and anti-hepatocellular carcinoma efficacy evaluation. Chaudhary CL; Lim D; Chaudhary P; Guragain D; Awasthi BP; Park HD; Kim JA; Jeong BS J Enzyme Inhib Med Chem; 2022 Dec; 37(1):844-856. PubMed ID: 35296193 [TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and anti-hepatocellular carcinoma activity of 3-arylisoquinoline alkaloids. Deng X; Luo T; Li Z; Wen H; Zhang H; Yang X; Lei F; Liu D; Shi T; Zhao Q; Wang Z Eur J Med Chem; 2022 Jan; 228():113985. PubMed ID: 34802836 [TBL] [Abstract][Full Text] [Related]
23. Synthesis and biological evaluation of phenyl substituted polyoxygenated xanthone derivatives as anti-hepatoma agents. Dai M; Yuan X; Kang J; Zhu ZJ; Yue RC; Yuan H; Chen BY; Zhang WD; Liu RH; Sun QY Eur J Med Chem; 2013 Nov; 69():159-66. PubMed ID: 24013415 [TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and biological evaluation of novel 1,3,4-trisubstituted pyrazole derivatives as potential chemotherapeutic agents for hepatocellular carcinoma. Harras MF; Sabour R Bioorg Chem; 2018 Aug; 78():149-157. PubMed ID: 29567429 [TBL] [Abstract][Full Text] [Related]
25. Keshari AK; Singh AK; Raj V; Rai A; Trivedi P; Ghosh B; Kumar U; Rawat A; Kumar D; Saha S Drug Des Devel Ther; 2017; 11():1623-1642. PubMed ID: 28615927 [TBL] [Abstract][Full Text] [Related]
26. Water-soluble derivatives of evodiamine: Discovery of evodiamine-10-phosphate as an orally active antitumor lead compound. Chen S; Bi K; Wu S; Li Y; Huang Y; Sheng C; Dong G Eur J Med Chem; 2021 Aug; 220():113544. PubMed ID: 34052678 [TBL] [Abstract][Full Text] [Related]
27. The Antitumor Effects of Britanin on Hepatocellular Carcinoma Cells and its Real-Time Evaluation by In Vivo Bioluminescence Imaging. Li H; Du G; Yang L; Pang L; Zhan Y Anticancer Agents Med Chem; 2020; 20(9):1147-1156. PubMed ID: 32106805 [TBL] [Abstract][Full Text] [Related]
28. Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma. Omar HA; Zaher DM; Srinivasulu V; Hersi F; Tarazi H; Al-Tel TH Eur J Med Chem; 2017 Oct; 139():804-814. PubMed ID: 28865276 [TBL] [Abstract][Full Text] [Related]
29. Design and synthesis of parthenolide and 5-fluorouracil conjugates as potential anticancer agents against drug resistant hepatocellular carcinoma. Ding Y; Li S; Ge W; Liu Z; Zhang X; Wang M; Chen T; Chen Y; Zhang Q Eur J Med Chem; 2019 Dec; 183():111706. PubMed ID: 31553932 [TBL] [Abstract][Full Text] [Related]
30. 9-bis[2-(pyrrolidin-1-yl)ethoxy]-6-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-11H-indeno[1, 2-c]quinolin-11-one (BPIQ), A Quinoline Derivative Inhibits Human Hepatocellular Carcinoma Cells by Inducing ER Stress and Apoptosis. Chang WT; Fong Y; Chuang SC; Chou CK; Chou HL; Yang CF; Tseng CH; Chen YL; Chiu CC Anticancer Agents Med Chem; 2017; 17(5):692-700. PubMed ID: 27491935 [TBL] [Abstract][Full Text] [Related]
31. A polymeric prodrug of cisplatin based on pullulan for the targeted therapy against hepatocellular carcinoma. Wang Y; Liu Y; Liu Y; Zhou W; Wang H; Wan G; Sun D; Zhang N; Wang Y Int J Pharm; 2015 Apr; 483(1-2):89-100. PubMed ID: 25681730 [TBL] [Abstract][Full Text] [Related]
32. Growth inhibitor of human hepatic carcinoma HepG2 cells by evodiamine is associated with downregulation of PRAME. Zhu H; Ge K; Lu J; Jia C Naunyn Schmiedebergs Arch Pharmacol; 2019 Dec; 392(12):1551-1560. PubMed ID: 31359090 [TBL] [Abstract][Full Text] [Related]
34. A naphthalimide-polyamine conjugate preferentially accumulates in hepatic carcinoma metastases as a lysosome-targeted antimetastatic agent. Ma J; Li L; Yue K; Zhang Z; Su S; Chen Y; Yu L; Zhang P; Ma R; Li Y; Ma Y; Jia H; Wang C; Wang J; Xie S Eur J Med Chem; 2021 Oct; 221():113469. PubMed ID: 33965862 [TBL] [Abstract][Full Text] [Related]
35. Hepatocellular Carcinoma Targeting and Pharmacodynamics of Paclitaxel Nanoliposomes Modified by Glycyrrhetinic Acid and Ferric Tetroxide. Zhao L; Liang L; Guo M; Li M; Yu X; Wang Y; Wang Y Curr Top Med Chem; 2021 Oct; 21(14):1268-1284. PubMed ID: 34620053 [TBL] [Abstract][Full Text] [Related]
36. Structural simplification of evodiamine: Discovery of novel tetrahydro-β-carboline derivatives as potent antitumor agents. Ma Z; Huang Y; Wan K; Zhu F; Sheng C; Chen S; Liu D; Dong G Bioorg Med Chem Lett; 2021 May; 40():127954. PubMed ID: 33744440 [TBL] [Abstract][Full Text] [Related]
37. Gypenoside L inhibits hepatocellular carcinoma by targeting the SREBP2-HMGCS1 axis and enhancing immune response. Xiao MY; Pei WJ; Li S; Li FF; Xie P; Luo HT; Hyun Yoo H; Piao XL Bioorg Chem; 2024 Sep; 150():107539. PubMed ID: 38861912 [TBL] [Abstract][Full Text] [Related]
38. MEK inhibition by cobimetinib suppresses hepatocellular carcinoma and angiogenesis in vitro and in vivo. Tong X; Wang Q; Wu D; Bao L; Yin T; Chen H Biochem Biophys Res Commun; 2020 Feb; 523(1):147-152. PubMed ID: 31836141 [TBL] [Abstract][Full Text] [Related]
39. Substituted indole derivatives as UNC-51-like kinase 1 inhibitors: Design, synthesis and anti-hepatocellular carcinoma activity. Zhao LY; Li SY; Zhou ZY; Han XY; Li K; Xue ST; Jiang JD Biomed Pharmacother; 2024 Sep; 178():117260. PubMed ID: 39116788 [TBL] [Abstract][Full Text] [Related]
40. A Critical YAP in Malignancy of HCC Is Regulated by Evodiamine. Yun UJ; Bae SJ; Song YR; Kim YW Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163776 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]